Mavik

Mavik is a brand name of trandolapril, approved by the FDA in the following formulation(s):

MAVIK (trandolapril - tablet; oral)

• 
  Manufacturer: ABBOTT
  
  Approval date: April 26, 1996
  
  Strength(s): 1MG ^[AB], 2MG ^[AB], 4MG ^[RLD][AB]

Has a generic version of Mavik been approved?

A generic version of Mavik has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Mavik and have been approved by the FDA:

trandolapril tablet; oral

• 
  Manufacturer: AUROBINDO PHARMA
  
  Approval date: June 12, 2007
  
  Strength(s): 1MG ^[AB], 2MG ^[AB], 4MG ^[AB]


• 
  Manufacturer: CIPLA
  
  Approval date: June 12, 2007
  
  Strength(s): 1MG ^[AB], 2MG ^[AB], 4MG ^[AB]


• 
  Manufacturer: COREPHARMA
  
  Approval date: June 12, 2007
  
  Strength(s): 1MG ^[AB], 2MG ^[AB], 4MG ^[AB]


• 
  Manufacturer: DR REDDYS LABS LTD
  
  Approval date: August 25, 2008
  
  Strength(s): 1MG ^[AB], 2MG ^[AB], 4MG ^[AB]


• 
  Manufacturer: EPIC PHARMA
  
  Approval date: June 18, 2008
  
  Strength(s): 1MG ^[AB], 2MG ^[AB], 4MG ^[AB]


• 
  Manufacturer: INVAGEN PHARMS
  
  Approval date: June 12, 2007
  
  Strength(s): 1MG ^[AB], 2MG ^[AB], 4MG ^[AB]


• 
  Manufacturer: LUPIN
  
  Approval date: June 12, 2007
  
  Strength(s): 1MG ^[AB], 2MG ^[AB], 4MG ^[AB]


• 
  Manufacturer: MYLAN
  
  Approval date: April 28, 2008
  
  Strength(s): 1MG ^[AB], 2MG ^[AB], 4MG ^[AB]


• 
  Manufacturer: TEVA PHARMS
  
  Approval date: December 12, 2006
  
  Strength(s): 1MG ^[AB], 2MG ^[AB], 4MG ^[AB]


• 
  Manufacturer: WATSON LABS
  
  Approval date: June 12, 2007
  
  Strength(s): 1MG ^[AB], 2MG ^[AB], 4MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Mavik. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Method of treating cardiac insufficiency using angiotensin-converting enzyme inhibitors
  Patent 5,744,496
  Issued: April 28, 1998
  Inventor(s): Henning; Rainer & Urbach; Hansjorg & Teetz; Volker & Geiger; Rolf & Scholkens; Bernward
  Assignee(s): Hoechst Aktiengesellschaft
  The invention relates to a method of treating cardiac insufficiency by using compounds of the formula I ##STR1## in which n is 1 or 2, R, R.sup.1, R.sup.2 and R.sup.3 are identical or different and each denote hydrogen or an organic radical and R.sup.4 and R.sup.5, together with the atoms carrying them, form a mono-, bi- or tri-cyclic heterocyclic ring system. The invention furthermore relates to compounds of the formula I and agents containing these for use in the treatment of the abovementioned disease.
  
  Patent expiration dates:
  
  
  • April 28, 2015
    
    ✓ 
    Patent use: CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE)
  
  

See also...

• Mavik Consumer Information (Wolters Kluwer)
• Mavik Consumer Information (Cerner Multum)
• Mavik Advanced Consumer Information (Micromedex)
• Mavik AHFS DI Monographs (ASHP)
• Trandolapril Consumer Information (Wolters Kluwer)
• Trandolapril Consumer Information (Cerner Multum)
• Trandolapril Advanced Consumer Information (Micromedex)
• Trandolapril AHFS DI Monographs (ASHP)